Global epidemiology and genetics of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide. Classically, HCC
develops in genetically susceptible individuals who are exposed to risk factors, especially in …
develops in genetically susceptible individuals who are exposed to risk factors, especially in …
Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission
Summary The Asia-Pacific region is home to more than half of the global population and
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …
Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia
Background & Aims Population-level evidence for the impact of direct-acting antiviral (DAA)
therapy on hepatitis C virus (HCV)-related disease burden is lacking. We aimed to evaluate …
therapy on hepatitis C virus (HCV)-related disease burden is lacking. We aimed to evaluate …
Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019
Background Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV)
incidence through a" treatment as prevention"(TasP) effect. We assessed changes in …
incidence through a" treatment as prevention"(TasP) effect. We assessed changes in …
Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study
Background Evaluating progress towards hepatitis C virus (HCV) elimination is critical. This
study estimated prevalence of current HCV infection and HCV treatment uptake among …
study estimated prevalence of current HCV infection and HCV treatment uptake among …
Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
Australia was one of the first countries to introduce government-funded unrestricted access
to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However …
to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However …
Australia needs to increase testing to achieve hepatitis C elimination
N Scott, R Sacks‐Davis, AJ Wade… - Medical Journal of …, 2020 - Wiley Online Library
Objectives To assess progress in Australia toward the 2030 WHO hepatitis C elimination
targets two years after the introduction of highly effective direct‐acting antiviral (DAA) …
targets two years after the introduction of highly effective direct‐acting antiviral (DAA) …
Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta‐analysis
MT Yousafzai, S Bajis, M Alavi, J Grebely… - Journal of viral …, 2021 - Wiley Online Library
Abstract The World Health Organization 2030 targets for hepatitis C virus (HCV) elimination
include diagnosing 90% of people with HCV and treating 80% of people diagnosed with …
include diagnosing 90% of people with HCV and treating 80% of people diagnosed with …
High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia
Background & Aims High HCV treatment uptake among people at most risk of transmission
is essential to achieve elimination. We aimed to characterise subpopulations of people with …
is essential to achieve elimination. We aimed to characterise subpopulations of people with …
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people who inject drugs
Background The aim of this analysis was to calculate the incidence of hepatitis C virus
(HCV) reinfection and associated factors among 2 clinical trials of HCV direct-acting antiviral …
(HCV) reinfection and associated factors among 2 clinical trials of HCV direct-acting antiviral …